Prevalence of anxiety and depression symptoms among patients with psoriasis in Kabul, Afghanistan
2024; Wiley; Volume: 63; Issue: 8 Linguagem: Inglês
10.1111/ijd.17343
ISSN1365-4632
AutoresAhmad Khalid Aalemi, Alison K. Wright, Khatera Habib, Nahid Raofi, Darren M. Ashcroft, C.E.M. Griffiths,
Tópico(s)Circadian rhythm and melatonin
ResumoInternational Journal of DermatologyEarly View Letter to the Editor Prevalence of anxiety and depression symptoms among patients with psoriasis in Kabul, Afghanistan Ahmad Khalid Aalemi, Corresponding Author Ahmad Khalid Aalemi [email protected] orcid.org/0000-0003-0111-634X Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UKSearch for more papers by this authorAlison K. Wright, Alison K. Wright orcid.org/0000-0002-8418-8332 Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UKSearch for more papers by this authorKhatera Habib, Khatera Habib Department of Dermatology, Maiwand Teaching Hospital, Kabul University of Medical Sciences, Kabul, AfghanistanSearch for more papers by this authorNahid Raofi, Nahid Raofi Department of Dermatology, Maiwand Teaching Hospital, Kabul University of Medical Sciences, Kabul, AfghanistanSearch for more papers by this authorDarren M. Ashcroft, Darren M. Ashcroft orcid.org/0000-0002-2958-915X Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UKSearch for more papers by this authorChristopher E. M. Griffiths, Christopher E. M. Griffiths orcid.org/0000-0001-5371-4427 Centre for Dermatology Research, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester, UK Department of Dermatology, King's College Hospital, King's College London, London, UKSearch for more papers by this author Ahmad Khalid Aalemi, Corresponding Author Ahmad Khalid Aalemi [email protected] orcid.org/0000-0003-0111-634X Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UKSearch for more papers by this authorAlison K. Wright, Alison K. Wright orcid.org/0000-0002-8418-8332 Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UKSearch for more papers by this authorKhatera Habib, Khatera Habib Department of Dermatology, Maiwand Teaching Hospital, Kabul University of Medical Sciences, Kabul, AfghanistanSearch for more papers by this authorNahid Raofi, Nahid Raofi Department of Dermatology, Maiwand Teaching Hospital, Kabul University of Medical Sciences, Kabul, AfghanistanSearch for more papers by this authorDarren M. Ashcroft, Darren M. Ashcroft orcid.org/0000-0002-2958-915X Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UKSearch for more papers by this authorChristopher E. M. Griffiths, Christopher E. M. Griffiths orcid.org/0000-0001-5371-4427 Centre for Dermatology Research, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester, UK Department of Dermatology, King's College Hospital, King's College London, London, UKSearch for more papers by this author First published: 23 June 2024 https://doi.org/10.1111/ijd.17343 Conflict of interest: CEMG has received research grants and/or honoraria from Abbvie, Almirall, Anaptysbio, Artax, Boehringer-Ingelheim, Boots UK Ltd, Bristol Meyers Squibb, Evelo Biosciences, GSK, Inmagene, Janssen, LEO Foundation, Lilly, ONO Pharmaceuticals, Novartis, Pfizer, and UCB. DMA has received research grant funding from the Leo Foundation, UCB, Amgen, Almirall, Janssen, Boehringer–Ingelheim, and Bristol Myers Squibb. Funding source: None. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020; 369:m1590. 10.1136/bmj.m1590 PubMedGoogle Scholar 2Picardi A, Abeni D. Stressful life events and skin diseases: disentangling evidence from myth. Psychother Psychosom. 2001; 70: 118–136. 10.1159/000056237 CASPubMedWeb of Science®Google Scholar 3Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978; 157: 238–244. 10.1159/000250839 CASPubMedWeb of Science®Google Scholar 4Montazeri A, Vahdaninia M, Ebrahimi M, Jarvandi S. The Hospital Anxiety and Depression Scale (HADS): translation and validation study of the Iranian version. Health Qual Life Outcomes. 2003; 1: 14. 10.1186/1477-7525-1-14 PubMedGoogle Scholar 5Ferreira BR, Pio-Abreu JL, Reis JP, Figueiredo A. Analysis of the prevalence of mental disorders in psoriasis: the relevance of psychiatric assessment in dermatology. Psychiatr Danub. 2017; 29: 401–406. 10.24869/psyd.2017.401 PubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation
Referência(s)